Ulcerative dermatosis of Shetland sheepdogs and rough collies is an inflammatory, erosive skin disorder of unknown etiology.
When described in 1995, it was thought to be a variant of canine familial dermatomyositis.1 But in 2001, researchers compared the clinicopathologic findings in five Shetland sheepdogs and three rough collies with
this syndrome with those in seven Shetland sheepdogs and one rough collie with dermatomyositis and found that the two diseases
were distinct.2,3 First, ulcerative dermatosis of Shetland sheepdogs and rough collies tended to affect older dogs (the mean age of onset was
5 years), while dermatomyositis affected younger dogs (usually dogs less than 6 months old). Second, ulcerative dermatosis
of Shetland sheepdogs and rough collies first occurred in the summer months in seven of the eight dogs, while the occurrence
of dermatomyositis was not seasonal. Third, the histologic pattern of ulcerative dermatosis of Shetland sheepdogs and rough
collies was a lymphocyte-rich interface dermatitis with vesiculation at the dermal-epidermal junction, while the histologic
pattern of dermatomyositis was a cell-poor interface dermatitis with follicular atrophy.
The eight dogs with ulcerative dermatosis were presented for evaluation of serpiginous ulcers on their ventral abdomens, groins,
and medial thighs (Figure 1).3 Ulcers were noted on the mucocutaneous junctions in six of the dogs, on the inner pinnae in five of the dogs, and in the
oral cavity in three of the dogs. Extensive ulceration can also be seen with this disease, and secondary bacterial colonization,
bacteremia, and sepsis were described in one dog.3
Figure 1 : Ulcerative lesions on a collie's ventral abdomen.
In contrast, the skin lesions associated with dermatomyositis often first develop on areas of mechanical trauma, such as the
periocular region, tail tip, face, muzzle, ear tips, and tarsal regions.3 Although oral ulcers may occur, they are rare. The most commonly observed lesions in dogs with dermatomyositis are alopecia,
erythema, scaling, and crusting. In some dogs with dermatomyositis, the lesions can be severe and ulceration can occur.
A recent study reported on the clinical treatment of and prognosis in 11 dogs with ulcerative dermatosis of Shetland sheepdogs
and rough collies; eight of these dogs were from the 2001 study.4 Three of the 11 dogs were euthanized for reasons related to the disease; one of the three was euthanized before any therapy
was initiated. In the remaining eight dogs, a variety of combination therapies were used, and eventually all dogs required
systemic therapy. Of the dogs in which follow-up was reported, a 75% to 100% response was seen. The best long-term treatment
was achieved with oral prednisone (2 mg/kg/day) and azathioprine (1 to 2 mg/kg/day). Prednisone was administered initially,
and azathioprine was added for its corticosteroid-sparing effect or for additional immunosuppressive effects. All of the dogs
receiving long-term systemic therapy experienced adverse effects and required long-term topical or systemic antibacterial
treatment. Relapses were reported in subsequent summers. In short, this immune-mediated disease was chronic and somewhat debilitating
but still manageable.
Clinicians have long recognized ulcerative skin diseases in collies and Shetland sheepdogs. The differential diagnoses for
ulcerative dermatoses involving the oral mucosa or axillary or inguinal regions include bullous pemphigoid, systemic lupus
erythematosus, erythema multiforme, and pemphigus vulgaris. Making a definitive diagnosis can be difficult if no intact ulcers
or vesicles are found. It has been suggested that ulcerative dermatosis of Shetland sheepdogs and rough collies be renamed
canine vesicular cutaneous lupus erythematosus because of its similarities to a disease in people called subacute cutaneous lupus erythematosus.3-5
Regardless of the disease's name, it is important to recognize that the disease has a breed predilection and may appear similar
to the other immune-mediated diseases mentioned above and be treated similarly with a combination of immunosuppressive therapies.
The efficacy of cyclosporine in this disease is unknown. Systemic antibiotics are indicated if secondary bacterial colonization
of the skin has occurred. Bacteremia and sepsis should be considered and addressed before you initiate immunosuppressive therapy.
This disease needs to be differentiated from other immune-mediated diseases, such as systemic lupus erythematosus, which could
involve internal organs. A thorough diagnostic evaluation (medical and dermatologic) can help identify concurrent or potentially
complicating problems. As with any immune-mediated disease, every effort should be made to determine a definitive diagnosis
because it may affect the drug selection and prognosis.